Travere Therapeutics, Inc. TVTX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s total liabilities & equity?
- Travere Therapeutics, Inc. (TVTX) reported total liabilities & equity of $555.19M in Q1 2026.
- How has Travere Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
- Travere Therapeutics, Inc.'s total liabilities & equity increased by 1.2% year-over-year, from $548.8M to $555.19M.
- What is the long-term trend for Travere Therapeutics, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s total liabilities & equity has grown at a -0.1% compound annual growth rate (CAGR), from $607.44M to $605.19M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.